JP2002544759A - カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法 - Google Patents

カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法

Info

Publication number
JP2002544759A
JP2002544759A JP53899798A JP53899798A JP2002544759A JP 2002544759 A JP2002544759 A JP 2002544759A JP 53899798 A JP53899798 A JP 53899798A JP 53899798 A JP53899798 A JP 53899798A JP 2002544759 A JP2002544759 A JP 2002544759A
Authority
JP
Japan
Prior art keywords
mbi
peptide
antibiotic
group
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53899798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544759A5 (enExample
Inventor
アール． フレイサー，ジャネット
エイチ．ピー． ウエスト，マイケル
ジェイ． マクニコル，パトリシア
Original Assignee
マイクロロジックス バイオテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/915,314 external-priority patent/US6180604B1/en
Application filed by マイクロロジックス バイオテック インコーポレイテッド filed Critical マイクロロジックス バイオテック インコーポレイテッド
Publication of JP2002544759A publication Critical patent/JP2002544759A/ja
Publication of JP2002544759A5 publication Critical patent/JP2002544759A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP53899798A 1997-03-10 1998-03-10 カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法 Pending JP2002544759A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4064997P 1997-03-10 1997-03-10
US08/915,314 US6180604B1 (en) 1996-08-21 1997-08-20 Compositions and methods for treating infections using analogues of indolicidin
US6009997P 1997-09-26 1997-09-26
US09/030,619 1998-02-25
US60/040,649 1998-02-25
US08/915,314 1998-02-25
US60/060,099 1998-02-25
US09/030,619 US6503881B2 (en) 1996-08-21 1998-02-25 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
PCT/CA1998/000190 WO1998040401A2 (en) 1997-03-10 1998-03-10 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics

Publications (2)

Publication Number Publication Date
JP2002544759A true JP2002544759A (ja) 2002-12-24
JP2002544759A5 JP2002544759A5 (enExample) 2005-11-10

Family

ID=27487830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53899798A Pending JP2002544759A (ja) 1997-03-10 1998-03-10 カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法

Country Status (9)

Country Link
US (3) US6503881B2 (enExample)
EP (1) EP0966481B1 (enExample)
JP (1) JP2002544759A (enExample)
AT (1) ATE333464T1 (enExample)
AU (1) AU6604798A (enExample)
CA (1) CA2282807A1 (enExample)
DE (1) DE69835279T2 (enExample)
ES (1) ES2264198T3 (enExample)
WO (1) WO1998040401A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502262A (ja) * 2003-08-14 2007-02-08 ディアトス （ソシエテ アノニム） ペプチド及び有利に疎水性の抗菌剤からなる特にグラム陰性菌を制御するための抗菌組成物
JP2012500642A (ja) * 2008-08-26 2012-01-12 カトリック ユニバーシテイト ルーベン ケイ．ユー． ルーベン アール アンド ディー 抗微生物剤
JP2016525369A (ja) * 2013-07-31 2016-08-25 シージェイ チェイルジェダン コーポレーションＣｊ Ｃｈｅｉｌｊｅｄａｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 超高圧を用いた野菜類食品の製造方法
JP2016536310A (ja) * 2013-10-31 2016-11-24 ハチソン バイオフィルム メディカル ソリューションズ リミテッド バイオフィルムの予防及び分散

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6172185B1 (en) * 1998-05-20 2001-01-09 University Of British Columbia Antimicrobial cationic peptide derivatives of bactenecin
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
WO2000026344A1 (en) * 1998-10-30 2000-05-11 Interlink Biotechnologies Llc Peptides with enhanced stability to protease degradation
US6946261B1 (en) 1998-11-20 2005-09-20 Migenix Inc. Efficient methods for producing anti-microbial cationic peptides in host cells
CN1670217A (zh) * 1999-02-03 2005-09-21 特瓦药厂有限公司 经微生物学方法制备假单胞菌酸a抗生素的方法
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US20030008369A1 (en) * 1999-03-03 2003-01-09 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases
EP1163352A1 (en) * 1999-03-17 2001-12-19 University Of Victoria Innovation And Development Corporation Transgenic plants that are resistant to a broad spectrum of pathogens
US6835868B1 (en) 1999-03-17 2004-12-28 University Of Victoria Innovation And Development Corporation Transgenic plants expressing dermaseptin peptides providing broad spectrum resistance to pathogens
EP1180013B1 (en) * 1999-05-27 2006-03-08 Biocompatibles UK Limited Local drug delivery
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
AU782915B2 (en) * 1999-12-20 2005-09-08 Sa Majeste La Reine Du Chef Du Canada - Agriculture Et Agroalimentaire Canada Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
WO2001053509A2 (en) * 2000-01-21 2001-07-26 The Wistar Institute Of Anatomy And Biology Biocidal molecules, macromolecular targets and methods of production and use
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
US6777592B2 (en) * 2000-04-14 2004-08-17 E.I. Du Pont Denemours And Company Arthropod defensins of Scolopendra canidens, Vaejovis carolinianus, and Argiope spp.
DE10030781A1 (de) * 2000-06-29 2002-01-17 Hassan Jomaa Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
DE10042853A1 (de) * 2000-08-30 2002-04-25 Florian Lang Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen
CN1455673A (zh) * 2001-01-05 2003-11-12 凯敏工业公司 分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物
WO2002064183A1 (en) * 2001-02-09 2002-08-22 Johnson & Johnson Vision Care, Inc. Biomedical devices with antimicrobial cationic peptide and protein coatings
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
HUP0500797A2 (en) * 2001-06-21 2007-06-28 Biogal Gyogyszergyar Metabolic controlled fermentation process for pseudomonic acid production
EP1401478A2 (en) * 2001-06-22 2004-03-31 The Hospital for Sick Children Antimicrobial peptides
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US8933029B2 (en) * 2001-08-24 2015-01-13 Carrus Capital Corporation Antimicrobial and anti-inflammatory peptides
KR100438416B1 (ko) * 2001-09-19 2004-07-02 학교법인조선대학교 Ｃａ－ｍａ 펩타이드의 아미노산 중 하나 또는 그 이상을치환하여 ＋ 전극과 소수성 영역이 증가된 신규한펩타이드 및 그를 포함하는 약학적 조성물
ATE554755T1 (de) * 2001-10-05 2012-05-15 Steris Inc In vitro verfahren, um gegen prionen gerichtete behandlungen abzuschätzen
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
EP1455769A4 (en) 2001-12-28 2004-09-22 Biogal Gyogyszergyar METHOD FOR PRODUCING CRYSTALLINE AND AMORPHIC MUPIROCIN CALCIUM
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20030219854A1 (en) * 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
EP1487432B1 (en) * 2002-03-26 2013-03-06 Eastern Virginia Medical School Suramin and derivatives thereof as topical microbicide and contraceptive
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
FR2839311A1 (fr) * 2002-05-06 2003-11-07 Entomed Peptides antibacteriens, genes codant les peptides, vecteurs, organismes transformes, leurs preparations et les compositions les contenant
EP1360961A1 (en) * 2002-05-07 2003-11-12 AM-Pharma B.V. Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
BR0316776A (pt) * 2002-12-10 2005-10-25 Biosynexus Inc Formula para anti-infeccioso tópico
DE10260537A1 (de) * 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
EP1608377B1 (en) * 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6989370B2 (en) * 2003-05-01 2006-01-24 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
SE0301431D0 (sv) 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
CN101415724B (zh) * 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
US20060121083A1 (en) * 2003-07-18 2006-06-08 Technion Research & Development Foundation Ltd. Anti-microbial medical implants and uses thereof
AU2003904225A0 (en) * 2003-08-08 2003-08-21 Ripetech Pty Limited Method for reducing precure during the curing of thermosetting resins
FR2858772A1 (fr) * 2003-08-14 2005-02-18 Diatos Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
US20050108047A1 (en) * 2003-11-19 2005-05-19 Vvii Newco 2003, Inc. Business methods for commercializing antibiotics
US7455840B2 (en) * 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005090385A2 (en) * 2004-03-18 2005-09-29 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
ATE458476T1 (de) * 2004-06-01 2010-03-15 Teva Gyogyszergyar Zartkoeruen Verfahren für die zubereitung der amorphen form eines medikamentes
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
DK1927597T3 (en) * 2004-08-18 2017-02-13 Novabiotics Ltd ANTIBACTERIAL PEPTIDES
US7700308B2 (en) * 2004-09-16 2010-04-20 University Of Washington Methods for determining susceptibility to dental caries
WO2006049580A1 (en) * 2004-11-04 2006-05-11 National University Of Singapore Anticoagulant peptides
EP1657249A1 (en) * 2004-11-10 2006-05-17 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Antibiotic drosocin derivatives
SE0402807D0 (sv) * 2004-11-17 2004-11-17 Dermagen Ab Novel antimicrobial peptides
US8252737B2 (en) 2004-12-15 2012-08-28 The Regents Of The University Of Colorado Antimicrobial peptides and methods of use
EP1858488B2 (en) * 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
CA2603179A1 (en) * 2005-04-05 2006-10-12 The Scripps Research Institute Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases
CA2617133C (en) 2005-07-28 2014-09-30 Biosynexus Incorporated Compositions and methods for treating bacteria
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
JP2009526045A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規抗菌ペプチド及びその使用
JP2009526046A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規分子
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
AU2007250558B2 (en) 2006-05-16 2012-10-25 Pergamum Ab Improved antimicrobial peptides
IL176303A0 (en) * 2006-06-14 2006-10-05 Shmuel Shraga Pharmaceutical composition for the treatment of otomycosis
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008033119A1 (en) * 2006-09-12 2008-03-20 Chaperone Technologies, Inc. Novel combinations of dnak inhibitors with known antibacterial agents
US20080139518A1 (en) * 2006-12-04 2008-06-12 Concert, Llc Topical compositions for treatment of skin conditions
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
WO2009009156A2 (en) * 2007-07-06 2009-01-15 Laclede, Inc. Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages
DE102007036128A1 (de) * 2007-07-23 2009-02-12 Universität Leipzig Antibiotische Peptide
KR20100059863A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도
WO2009033667A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
DE102008031283A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten
DE102008031284A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit der Giardiose
US20100008897A1 (en) * 2008-07-09 2010-01-14 Susan Daly Composition for providing a benefit to a keratin-containing substrate
WO2010042534A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides and methods of use
EP2437770A4 (en) * 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
US20120195872A1 (en) * 2009-06-26 2012-08-02 Lysando Ag Antimicrobial agents
TW201125577A (en) * 2009-12-02 2011-08-01 Novozymes As Use of defensins for treatment of infective endocarditis
RU2013126706A (ru) 2010-11-15 2014-12-27 Рамот Ат Тель-Авив Юниверсити Лтд. Дипептидные аналоги для лечения состояний, ассоциированных с образованием амилоидных фибрилл
US20130345249A1 (en) * 2011-01-15 2013-12-26 The Regents Of The University Of California Formulations for the prevention and treatment of Wolbachia-related disease
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9603896B2 (en) 2012-12-03 2017-03-28 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
JP6405365B2 (ja) 2013-04-16 2018-10-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ ペプチド化合物及びその製造方法及びその使用
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
CA2911919A1 (en) 2013-05-10 2014-11-13 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antimicrobial peptide
US10059752B2 (en) * 2013-10-14 2018-08-28 University Of Houston System Esculentin 1a derivatives and uses thereof
US10751440B2 (en) * 2013-10-14 2020-08-25 University Of Houston System Esculentin 1a derivatives and uses thereof
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
US10791740B2 (en) 2014-06-06 2020-10-06 The Curators Of The University Of Missouri Enhancement of antibiotic efficacy
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
WO2016132359A2 (en) * 2015-02-22 2016-08-25 Omnix Medical Ltd. Antimicrobial peptides
KR101773390B1 (ko) * 2015-05-08 2017-08-31 동아인코팜 주식회사 여드름 개선용 화장료 조성물
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
US12594285B2 (en) 2016-02-25 2026-04-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
ITUA20163612A1 (it) * 2016-05-19 2017-11-19 Icf Srl Nuovi composti attivi contro microorganismi patogeni
WO2017223098A1 (en) 2016-06-21 2017-12-28 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
CN106589135B (zh) * 2016-11-25 2018-08-28 东北农业大学 一种靶向抗菌肽及其制备方法和应用
WO2018140518A1 (en) 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions and related methods for controlling vector-borne diseases
CN110831432A (zh) 2017-01-24 2020-02-21 旗舰创业创新五公司 用于农业的组合物和相关方法
AU2018212575B2 (en) 2017-01-24 2022-07-07 Flagship Pioneering Innovations V, Inc. Compositions and related methods for controlling vector-borne diseases
UA127733C2 (uk) * 2017-01-24 2023-12-20 Флегшіп Пайонірінг Інновейшнз V, Інк. Композиції і відповідні способи для сільського господарства
BR122022016119B1 (pt) 2017-01-24 2023-11-21 Flagship Pioneering Innovations V, Inc Métodos para aumentar o perfil nutricional de um inseto e para aumentar a taxa de desenvolvimento de um inseto e usos de bactérias
CA3048497A1 (en) 2017-02-24 2018-08-30 Flagship Pioneering Innovations V, Inc. Compositions and related methods for modulating endosymbionts
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
CN108434438B (zh) * 2018-06-22 2020-08-25 安徽科技学院 抗菌肽在制备治疗幽门螺杆菌病的药物中的用途以及药物组合物
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
US11471433B1 (en) 2019-08-01 2022-10-18 Flagship Pioneering Innovations V, Inc. Postbiotic compositions and related methods for agriculture
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
EP4213876A4 (en) * 2020-09-17 2024-09-25 Board of Regents, The University of Texas System PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN
WO2026042045A1 (en) 2024-08-22 2026-02-26 Itc Limited Indolicidine-containing compositions for personal care/hygiene applications
WO2026041926A1 (en) 2024-08-22 2026-02-26 Itc Limited A synergistic combination of an antimicrobial peptide and actives for hygiene applications
WO2026041925A1 (en) 2024-08-22 2026-02-26 Itc Limited A synergistic composition of an antimicrobial peptide (amp) and natural active
CN119350439B (zh) * 2024-08-26 2025-12-30 海南大学 一种具有抗白色念珠菌活性的短链抗菌肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506645A (ja) * 1990-02-23 1993-09-30 ブリストル―マイアーズ　スクイブ　カンパニー β―ラクタム抗生物質に感受性の生物により引き起こされる感染を治療するための組成物および方法
WO1995022338A1 (en) * 1994-02-16 1995-08-24 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
WO1996038473A2 (en) * 1995-06-02 1996-12-05 University Of British Columbia Antimicrobial cationic peptides
WO1997008199A2 (en) * 1995-08-23 1997-03-06 University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
DK0759774T3 (da) 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
CA2181164C (en) 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
WO1999043357A1 (en) 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506645A (ja) * 1990-02-23 1993-09-30 ブリストル―マイアーズ　スクイブ　カンパニー β―ラクタム抗生物質に感受性の生物により引き起こされる感染を治療するための組成物および方法
WO1995022338A1 (en) * 1994-02-16 1995-08-24 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
WO1996038473A2 (en) * 1995-06-02 1996-12-05 University Of British Columbia Antimicrobial cationic peptides
WO1997008199A2 (en) * 1995-08-23 1997-03-06 University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6009022968, Ｂｉｏｃｈｅｍｉｓｔｒｙ, 1992, Ｖｏｌ．３１， Ｎｏ．４７, ｐ．１１７１３−１１７２０ *
JPN6009022969, Ｊ．Ｍｅｄ．Ｃｈｅｍ．, 1982, Ｖｏｌ．２５， Ｎｏ．９, ｐ．１０２２−１０２７ *
JPN6009022970, Ｐｅｐｔｉｄｅｓ, 1983, ｐ．６２７−６３０ *
JPN7007001527, Ｃｌｉｎ．Ｉｎｆｅｃｔ Ｄｉｓｅａｓｅｓ, 199701, Ｖｏｌ．２４（Ｓｕｐｐｌ．１）, ｐ．１４８−１５０ *
JPN7007001528, Ａｎｔｉｍｉｃｏｂｉａｌ Ａｇｅｎｔｓ Ｃｈｅｍｏｔｈｅｒａｐｙ, 199608, Ｖｏｌ．４０， Ｎｏ．８, ｐ．１８０１−１８０５ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502262A (ja) * 2003-08-14 2007-02-08 ディアトス （ソシエテ アノニム） ペプチド及び有利に疎水性の抗菌剤からなる特にグラム陰性菌を制御するための抗菌組成物
JP2012500642A (ja) * 2008-08-26 2012-01-12 カトリック ユニバーシテイト ルーベン ケイ．ユー． ルーベン アール アンド ディー 抗微生物剤
JP2013081465A (ja) * 2008-08-26 2013-05-09 Katholieke Univ Leuven Ku Leuven R&D 抗微生物剤
JP2016525369A (ja) * 2013-07-31 2016-08-25 シージェイ チェイルジェダン コーポレーションＣｊ Ｃｈｅｉｌｊｅｄａｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 超高圧を用いた野菜類食品の製造方法
JP2016536310A (ja) * 2013-10-31 2016-11-24 ハチソン バイオフィルム メディカル ソリューションズ リミテッド バイオフィルムの予防及び分散

Also Published As

Publication number Publication date
DE69835279D1 (de) 2006-08-31
US7309759B2 (en) 2007-12-18
US20030232750A1 (en) 2003-12-18
WO1998040401A3 (en) 1998-12-17
EP0966481A2 (en) 1999-12-29
US20110150780A1 (en) 2011-06-23
US6503881B2 (en) 2003-01-07
AU6604798A (en) 1998-09-29
DE69835279T2 (de) 2007-07-12
WO1998040401A2 (en) 1998-09-17
US20020035061A1 (en) 2002-03-21
ATE333464T1 (de) 2006-08-15
HK1025103A1 (en) 2000-11-03
EP0966481B1 (en) 2006-07-19
CA2282807A1 (en) 1998-09-17
ES2264198T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
ES2264198T3 (es) Composiciones y metodos para tratar infecciones utilizando peptidos cationicos a solas o en combinacion con antibioticos.
JP5684098B2 (ja) 抗菌性カチオン性ペプチドおよびそれらの処方物
US9872885B2 (en) Antimicrobial and anti-inflammatory peptides
AU2007272272B2 (en) Antimicrobial peptides
AU2002324752A1 (en) Antimicrobial cationic peptides and formulations thereof
JP2001500477A (ja) インドリシジンのアナログを用いて感染を処置するための組成物および方法
AU2002328203A1 (en) Antimicrobial and anti-inflammatory peptides
JP5140579B2 (ja) 病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
KR20070050941A (ko) Ｃａｐ18 유래의 항균 펩티드
HK1025103B (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
HK1102693A (en) Antimicrobial peptides derived from cap18

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050309

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810